Cell News and Research

RSS

Bortezomib lymphoma drug may be effective against bone cancer in children and teens: Study

A drug already approved for the treatment of lymphoma may also slow the growth of the most deadly bone cancer in children and teens, according to an early-stage study published online today in the International Journal of Cancer.

5 Nov 2009

Amgen announces the results for Phase 3 PRIME '203' trial of Vectibix

Amgen today announced that the Phase 3 PRIME "203" trial evaluating Vectibix® (panitumumab) administered in combination with FOLFOX (an oxaliplatin-based chemotherapy) as a first-line treatment of metastatic colorectal cancer (mCRC) failed to meet a secondary endpoint of overall survival.

5 Nov 2009

SpineSmith Partners signs product development agreement with GenOsteo

SpineSmith Partners has signed an initial agreement with GenOsteo, Inc. to co-develop a unique scaffold that mimics the structure of natural cancellous bone.

5 Nov 2009

Althea Technologies offers formulation development services

Althea Technologies, Inc., a leading provider of development and manufacturing services for biopharmaceutical products announced the addition of customized Formulation Development to the company's platform of services, which will be overseen by the newly appointed Dr. James Matsuura, Director of Formulation Development.

5 Nov 2009

Newborns' cries already bear the mark of their parents' language, reveals new study

From their very first days, newborns' cries already bear the mark of the language their parents speak, reveals a new study published online on November 5th in Current Biology, a Cell Press publication. The findings suggest that infants begin picking up elements of what will be their first language in the womb, and certainly long before their first babble or coo.

5 Nov 2009

Abraxis BioScience reports $96.6 million net revenues for third quarter of 2009

Abraxis BioScience, Inc., a fully integrated biotechnology company, today reported unaudited financial results for the third quarter ending September 30, 2009.

5 Nov 2009

Nanoparticles may cause DNA damage across a cellular barrier

Scientists have shown in the laboratory that metal nanoparticles damaged the DNA in cells on the other side of a cellular barrier. The nanoparticles did not cause the damage by passing through the barrier, but generated signalling molecules within the barrier cells that were then transmitted to cause damage in cells the other side of the barrier.

5 Nov 2009

FDA grants Abraxis BioScience orphan drug designation for ABRAXANE

Abraxis BioScience, Inc., a fully integrated biotechnology company, today announced that the Office of Orphan Products Development of the Food and Drug Administration (FDA) has granted orphan drug designation to the chemotherapy agent ABRAXANE® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) for the treatment of pancreatic cancer as well as stage IIB-IV melanoma.

5 Nov 2009

ARIAD Pharmaceuticals' SUCCEED trial of oral ridaforolimus on track

ARIAD Pharmaceuticals, Inc. today reported financial results for the third quarter and nine months ended September 30, 2009 and provided an update on corporate developments.

5 Nov 2009

New biosensor device may help in combating cancer

A powerful new biosensor developed by European researchers will help identify cells in the immune system that actively suppress tumour growth, then put them to use. Enlisting the patient's own immune system would be like sending reinforcements for resistance fighters.

5 Nov 2009

ArQule reports financial results for the fiscal quarter and nine months ended September 30, 2009

ArQule, Inc. today reported its results of operations for the fiscal quarter and nine months ended September 30, 2009.

5 Nov 2009

Idera Pharmaceuticals announces financial results for the third quarter of 2009

Idera Pharmaceuticals, Inc. today reported financial results for the third quarter and nine months ended September 30, 2009.

5 Nov 2009

Atrium Medical presents final results of its "COCTAIL study"

Atrium Medical Corporation is proud to announce the release of the final results of the "COCTAIL Study," a clinical study comparing local administration of an anti-platelet medication with the company's proprietary infusion balloon technology.

5 Nov 2009

Alnylam Pharmaceuticals presents new data related to its overall delivery research efforts

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it presented new data related to its overall delivery research efforts including the rational design of Mimetic Lipoprotein Particles, or MLPs, a novel technology for the systemic delivery of small interfering RNAs, or siRNAs, the molecules that mediate RNAi.

5 Nov 2009

Alliant Health Plans forges alliance with Alliant Sense

Alliant Health Plans, a not-for-profit health plan with a radically new approach focused on patient care, and Global Behavioral Solutions (gBehavior), the industry leader in the utilization of incentive-based behavior modification strategies, have formed an alliance to launch Alliant Sense, a wellness rewards program that motivates members and patients to make healthy life choices.

5 Nov 2009

Scientists identify molecular disparity between iPS cells and embryonic stem cells

The same genes that are chemically altered during normal cell differentiation, as well as when normal cells become cancer cells, are also changed in stem cells that scientists derive from adult cells, according to new research from Johns Hopkins and Harvard.

5 Nov 2009

Cell Therapeutics reports financial results for the third quarter and nine months ended September 30, 2009

Cell Therapeutics, Inc. today reported recent achievements and financial results for the third quarter and nine months ended September 30, 2009, which included a 45% decrease in the net loss attributable to common shareholders for the nine month period in 2009 compared to the same period in 2008.

5 Nov 2009

Cell News and Research

Bortezomib lymphoma drug may be effective against bone cancer in children and teens: Study

Amgen announces the results for Phase 3 PRIME '203' trial of Vectibix

SpineSmith Partners signs product development agreement with GenOsteo

Althea Technologies offers formulation development services

Newborns' cries already bear the mark of their parents' language, reveals new study

Abraxis BioScience reports $96.6 million net revenues for third quarter of 2009

Nanoparticles may cause DNA damage across a cellular barrier

FDA grants Abraxis BioScience orphan drug designation for ABRAXANE

ARIAD Pharmaceuticals' SUCCEED trial of oral ridaforolimus on track

New biosensor device may help in combating cancer

ArQule reports financial results for the fiscal quarter and nine months ended September 30, 2009

Idera Pharmaceuticals announces financial results for the third quarter of 2009

Atrium Medical presents final results of its "COCTAIL study"

Alnylam Pharmaceuticals presents new data related to its overall delivery research efforts

Alliant Health Plans forges alliance with Alliant Sense

Scientists identify molecular disparity between iPS cells and embryonic stem cells

Cell Therapeutics reports financial results for the third quarter and nine months ended September 30, 2009

Scientists identify a novel cellular source of atrial fibrillation

Scientists differentiate human embryonic stem cells into lung epithelial tissue using air-liquid interface

Patients with post-traumatic stress disorder can benefit from synthetic marijuana

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News